GlassScriptPhysician profile
Richard Plowey
NPI 1154532612
$20,740.00
in general payments reported to CMS, 2019-2025
30 companies · $1,882 in 2025
The $1,882 reported for 2025 was more than what 78% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $536 · 2021: $2,160 · 2022: $7,094 · 2023: $5,393 · 2024: $1,474 · 2025: $1,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,772 · Consulting Fee: $2,100 · Travel and Lodging: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,772.17 |
| Consulting Fee | $2,100.00 |
| Travel and Lodging | $877.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $9,306.24 | 2019-2025 | Prialt |
| Abbott Laboratories | $4,735.25 | 2019-2025 | Proclaim, Penta, Eterna |
| Medtronic, INC. | $1,552.85 | 2021-2025 | Intellis Adaptivestim, Synchromedii, Inceptiv |
| Relievant Medsystems, INC. | $1,526.74 | 2023 | Intracept |
| Appliedvr INC | $567.13 | 2024-2025 | Relievrx |
| Spr Therapeutics, INC | $514.73 | 2022-2025 | Sprint Pns System |
| Boston Scientific Corporation | $441.55 | 2019-2025 | Intracept, Wavewriter Alpha Prime 16 |
| Nevro Corp. | $364.00 | 2022-2023 | Senza |
| Si-Bone, INC. | $293.31 | 2019-2024 | |
| Medtronic USA, INC. | $279.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.82 | 2019-2025 | Relistor |
| Horizon Therapeutics Plc | $124.58 | 2020-2022 | |
| Virtus Pharmaceuticals LLC | $112.72 | 2021-2025 | Levorphanol Tartrate |
| Scilex Pharmaceuticals INC. | $102.30 | 2019-2021 | |
| Pfizer INC. | $99.50 | 2019-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $89.72 | 2025 | Qutenza |
| Nalu Medical, INC. | $79.47 | 2025 | Nalu Neurostimulation System |
| Collegium Pharmaceutical, INC. | $76.40 | 2022-2025 | Belbuca, Xtampza |
| Abbvie INC. | $73.42 | 2024-2025 | |
| Assertio Therapeutics, INC. | $41.25 | 2019 | |
| Axsome Therapeutics, INC. | $38.49 | 2022 | |
| Biodelivery Sciences International, INC. | $33.90 | 2020-2021 | |
| Mdd US Operations, LLC | $26.44 | 2019 | |
| Arbor Pharmaceuticals, INC. | $25.57 | 2019 | |
| Zyla Life Sciences, INC. | $19.83 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $18.97 | 2025 | |
| Globus Medical, INC. | $17.93 | 2025 | Senza |
| Arteriocyte Medical Systems, INC. | $16.06 | 2025 | Magellan |
| Pacira Pharmaceuticals Incorporated | $15.82 | 2023 | Zilretta, Iovera |
| Valinor Pharma, LLC | $13.30 | 2024 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Plowey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.